ecrin-mdr-crcClinical2017IPD Sharing (as of March 2022): NoMetastatic Colorectal CancerColorectal NeoplasmsMetastatic Colorectal CancerColorectal NeoplasmsInterventionalhttps://newmdr.ecrin.org/Study/2175119Taiwan7TSB-9-W1ECRIN MDRCompletedfalseTo Determine the MTD and to Evaluate the Safety, Efficacy and PK Profiles of TSB-9-W1 in Pre-treated Patients With mCRC.TSB-9-W1, prepared by Taiwan Sunpan Biotechnology Co., Ltd. (TSB) is a botanical drug and applied patent in the United States (US patent No. 7,138,428 B2), Japan (Patent No. 5441947) and Taiwan (Patent No. I432191 and I282280). The R&D laboratory in TSB is ISO/IEC 17025 certified by Taiwan Accreditation Foundation (TAF) and the laboratory number is 2026.The trade name of TSB-9-W1 is "IDS" in English, the registration number is 01472800 at 2011 by Intellectual Property Office (IPO), Taiwan. A phase I and pk study to determine the Maximum Tolerated Dose (MTD) and to evaluate the safety and efficacy profiles of TSB-9-W1 in pre-treated patients with metastatic colorectal cancer (mCRC). there are 5 cohorts and a minimal 2 patients and up to 30 patients are required at phase I. This is a single arm study. All eligible patients with mCRC will receive TSB-9-W1 treatment. Each treatment cycle is composed by a contiguous 2-day oral administration and a contiguous 3-day rest. Patient should take the study drug once daily before meal with approximately 250 ml or appropriate amount of water.2017-07-152175119NCT02249650